[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"magnetic-resonance-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:magnetic-resonance-imaging":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,47,82,110,137,159,177,200,227,249,274,303,333,351,376,407,428,448,472,495,522,546,571,595,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100530818","kinetics-of-urinary-excretion-of-gadolinium-contrast-agents-used-in-mri-examinations-100530818",false,"NCT06191731","Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations","GADODURABLE","Inclusion Criteria:\n\nPatients:\n\n* over 18 years of age\n* with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist\n* affiliated with a health insurance plan\n* have signed an informed consent form\n\nExclusion Criteria:\n\n* Patients:\n* with known allergy to gadolinium-based contrast agents (Gd-CAs)\n* with known severe renal impairment (GFR \\\u003C 30 mL\u002Fmin)\n* on dialysis\n* with urinary incontinence\n* with an ongoing urinary tract infection\n* under hydric or hydrosodic restriction\n* unable to urinate independently\n* Protected persons (under guardianship, curatorship or safeguard of justice)\n* Pregnant or breast-feeding women","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate in the study. If they agree, blood and urine samples are collected before Gd-CAs injection, and urine samples are collected between 0- and two-and-a-half-hours post-injection of Gd-CAs.",[27],"Magnetic Resonance Imaging",[29,30,31,32,33],"Contrast agents","Gadolinium","Recycling","MRI","Gadoteric acid","RECRUITING","2026-06-20",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2024-04-12",{"date":42,"type":21},"2028-04-12",{"name":44,"class":45},"Centre Hospitalier Régional Metz-Thionville","OTHER",2,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":4,"leadSponsor":78,"locationsCount":81},"100057075","study-of-new-magnetic-resonance-imaging-methods-of-the-brain-100057075","NCT00004577","Study of New Magnetic Resonance Imaging Methods of the Brain","Characterization of Brain Morphology and Activity Using Functional and Anatomical MRI Contrast","* INCLUSION CRITERIA:\n* 18 years of age and older\n* in good general health\n* able to understand the procedures and requirements and give informed consent\n\nEXCLUSION CRITERIA:\n\nAll Subjects will undergo a neurological physical and answer the Healthy volunteer form, and the most-recent version of the NMR safety screening form\n\nA subject will be excluded if he\u002Fshe:\n\n1. has any metal implant or objects of unknown identity or composition, or if it s known to be non-compatible with MRI, such as pacemakers, medication pumps, aneurysm clips, metallic prosthesis (such as heart valves or cochlear implants), certain orthopedic implants (pins and rods), shrapnel, or small metal fragments in the eye;\n2. has claustrophobia;\n3. cannot lie comfortably for up to 120 minutes;\n4. underwent brain surgery or suffered a traumatic head trauma;\n5. has migraines that require medication;\n6. has ever been hospitalized for a psychiatric disorder;\n7. has medical health problems such as pulmonary or airway disease, heart failure, coronary artery disease, and uncontrolled hypertension which would require physiological monitoring during the scan;\n8. has a history of any medical condition that could result in an emergency medical situation while undergoing the MRI scan;\n9. has hearing problems which would make it difficult to tolerate scanner noise;\n10. is pregnant;\n11. has body\u002Fmake-up tattoos (e.g. lips, eyebrows, eyeliner). Each tattoo will be considered on a case-to-case basis, taking into account of the age and location of the tattoo;\n12. has a sleep apnea diagnosis;\n13. has a neurological disorder, such as Stroke, Parkinson s, and Epilepsy;\n14. a member of the NINDS Laboratory of Functional and Molecular Imaging.\n\nThe contraindications to MRI at the various field strengths are almost identical, except the 7 T also excludes subjects with gold dental crowns.",true,"120 Years",{"count":57,"type":21},1100,"OBSERVATIONAL","The purpose of this investigation is to develop improved magnetic resonance imaging (MRI) techniques and hardware for studying brain function. MRI is a diagnostic tool that provides information about brain chemistry and physiology. This study will evaluate new MRI methods for monitoring blood flow to regions of the brain in response to simple tasks. The MRI machine used in this study is more powerful than those in most hospitals, permitting a higher visual resolution.\n\nNormal healthy volunteers over 18 years old may be eligible for this study. Candidates will be screened with a medical history and questionnaire, and a neurological examination. Study participants will have a yearly MRI scan. For this procedure, the subject lies on a stretcher that is moved into a donut-shaped machine with a strong magnetic field. A lightweight circular or rectangular coil-a device that improves the quality of the images-may be placed on the head. The scan time varies from 20 minutes to 3 hours; most scans last between 45 and 90 minutes. During the scan, the subject may perform simple tasks, such as listening to tapes, tapping a finger, moving a hand, watching a screen, or smelling a fragrance. More complex tasks may require thinking about tones or pictures and responding to them by pressing buttons.\n\nInformation from this study will be used to develop better imaging methods that will, in turn, permit a greater understanding of normal and abnormal brain behaviors.",[61,27,62,63,64,65],"Healthy Volunteer","Healthy","fMRI","Brain Mapping","Adult",[67,68,69,70,71,72],"Brain Morphology","Cerebral Blood Volume","Functional Imaging","Development","MEG","Natural History","2026-06-16",{"date":75,"type":38},"2026-06-17",{"date":77,"type":38},"2000-07-01",{"name":79,"class":80},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":54,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":81},"100640797","effects-of-ketogenic-diet-on-alcohol-intoxication-100640797","NCT07602270","Effects of Ketogenic Diet on Alcohol Intoxication","Inclusion Criteria:\n\n1. Age 21 years to 50 years old.\n2. Willingness to provide signed, informed consent and commit to completing study procedures. Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.\n\nExclusion Criteria:\n\n1. Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.\n2. Current DSM-5 diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.\n3. Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)\n4. Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).\n5. A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).\n6. Currently suffering from or has a history of stroke and\u002For stroke related spasticity.\n7. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).\n8. Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).\n9. Females who are pregnant or breast-feeding\n10. Contraindication to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his\u002F her back for up to 2 hrs.","21 Years","50 Years",{"count":91,"type":21},20,[24],"The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Participants will be asked to undergo \\~4 weeks of ketogenic diet intervention. The study involves three lab visits: Lab 1 before starting the diet, Lab 2 after about 2 weeks after starting the diet, and Lab 3 after being on the diet for 4 weeks. All of the labs will include an alcohol tolerance test, and blood draws. Lab 1 and Lab 3 will also include an Magnetic resonance imaging scan. Due to scheduling, study procedures at 2 and 4 weeks may occur +\u002F- 3 days. Magnetic resonance imaging (MRI) of the brain will measure levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Alcohol tolerance will be tested using a dose of alcohol (approximately 4-5 alcohol beverages) to will elevate breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol. Blood samples will be collected to measure varying metabolites.",[95,96,97,27,98],"Ketogenic Diet","Alcohol Drinking","Alcohol Use Disorder","Alcohol Intoxication",[95,100],"Alcohol tolerance test","2026-05-15",{"date":103,"type":38},"2026-05-22",{"date":105,"type":38},"2026-05-14",{"date":107,"type":21},"2030-05",{"name":109,"class":45},"University of Pennsylvania",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":81},"100218563","phase-2-ketamine-alcohol-in-treatment-resistant-depression-100218563","NCT02122562","Ketamine Alcohol (in Treatment-Resistant Depression)","Functional Neuroimaging of the Enhanced Antidepressant Efficacy of Ketamine in a Biologically-Enriched Subgroup","INCLUSION CRITERIA:\n\n1. 18 to 55 years of age.\n2. A level of understanding sufficient to agree to all required tests and examinations, sign an informed consent document and verify understanding by a score greater than or equal to 90% on the consent quiz.\n3. Diagnostic and Statistical Manual-4th Edition-Text Revision (DSM-IV-TR)) diagnosis of major depressive disorder (MDD), single-episode (296.30) or recurrent (296.20) without psychotic features based on clinical assessment and confirmed by a Structured Clinical Interview for the DSM-IV- Patient Version (SCID-P). Subjects must be experiencing a current major depressive episode of at least 2 weeks duration.\n4. Past failure of greater than or equal to one standard antidepressant trial based on the Antidepressant Treatment History Form (ATHF).\n5. MADRS score greater than or equal to 20 at baseline and the day of ketamine infusion.\n\nEXCLUSION CRITERIA:\n\n1. Inadequate knowledge of family mental and substance use history, e.g. adoption.\n2. Current psychotic features or prior diagnosis of a DSM-IV-TR psychotic spectrum disorder, e.g. schizophrenia, schizoaffective disorder, bipolar I disorder with psychotic features, MDD with psychotic features, or bipolar disorder, e.g. bipolar I disorder without psychotic features, bipolar II disorder and bipolar disorder not otherwise specified (NOS).\n3. Current\u002Factive DSM-IV-TR substance use disorder (except for caffeine or nicotine dependence).\n4. Pregnant or nursing women or women of childbearing potential not using at least one medically accepted means of contraception (to include oral, injectable, or implant birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal ligation, abstinence or partner with vasectomy).\n5. Serious, unstable medical conditions\u002Fproblems including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled hyper\u002Fhypothyroidism or active cancer.\n6. Presence of any medical illness likely to alter brain morphology and\u002For physiology (e.g., hypertension, diabetes) even if controlled by medications.\n7. Clinically significant abnormal laboratory tests.\n8. Subjects with one or more seizures without clear and resolved etiology and head injury with loss of consciousness for \\> 5 minutes or requiring hospitalization.\n9. Treatment with psychiatric medications, e.g. selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, benzodiazepines and antipsychotics, at least two weeks of study phase II.\n10. Treatment with fluoxetine within 5 weeks of study phase II.\n11. Treatment with device-based treatment for depression, e.g. electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and vagal nerve stimulation (VNS), within 4 weeks of study phase II.\n12. Lifetime history of deep brain stimulation.\n13. Treatment with any disallowed concomitant medications.\n14. Positive HIV test\n15. Presence of ferromagnetic implants, e.g, heart pacemaker or aneurysm clip, or other contraindications to magnetic resonance imaging (MRI), e.g. claustrophobia or hearing loss.\n16. Clinically-significant anatomical brain abnormalities detected on routine brain MRI.\n17. Subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk, or who have a MADRS item 10 score of greater than or equal to 4.\n18. A current NIMH employee\u002Fstaff or their immediate family member (N.B. former exclusion criteria likely to be no longer relevant at the University of Iowa Health Care).\n19. Currently engaged in an evidence-based structured psychotherapy for mood and\u002For anxiety disorders, e.g. cognitive-behavioral therapy (CBT) or interpersonal psychotherapy (IPT).\n\nAdditionally, the investigators may exclude or terminate any patient for clinical reasons.","55 Years",{"count":20,"type":21},[120],"PHASE2","A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD). A family history of an alcohol use disorder (Family History Positive, FHP) is one of the strongest identified predictors of an improved antidepressant response to ketamine. Like ketamine, alcohol is a functional NMDA receptor antagonist. FHP is associated with differential response to ketamine, e.g. blunted psychotomimetic side effects. One of the primary mechanistic hypotheses for ketamine's antidepressant action is the acute intrasynaptic release of glutamate from major output neurons, e.g. cortical pyramidal cells. Preliminary clinical studies have demonstrated this acute glutamate \"surge\" in response to subanesthetic dose ketamine. Based on these findings, the investigators hypothesize that ketamine's enhanced antidepressant efficacy in FHP TRD subjects is, at least in part, attributable to increased glutamate release relative to TRD subjects without a family history of alcohol use disorder (Family History Negative, FHN). To test this hypothesis, the investigators have designed a now two-site, open-label study of 18-55-year-old medically and neurologically healthy, currently moderately-to-severely depressed TRD patients. In total, the investigators plan to recruit 25 FHP and 25 FHN TRD subjects. All subjects must not have a current substance use disorder (except nicotine or caffeine). The experimental portion consists of two phases. The preliminary first phase is a medication taper (if needed) and psychotropic medication-free period. The experimental second phase comprises one subanesthetic dose (0.5mg\u002Fkg x 40 minute) ketamine infusion. The ketamine infusion will occur during 7T-magnetic resonance imaging (MRI), both resting-state functional MRI (rs-fMRI) and magnetic resonance spectroscopy (MRS) to detect glutamate in the ventromedial prefrontal cortex\u002Fventral anterior cingulate cortex (vmPFC\u002FvACC). The primary outcome measure is group mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from pre-ketamine infusion (baseline) to one-week post-infusion, where the investigators observed ketamine's greatest antidepressant effect in FHP TRD. Additional outcome measures are vmPFC\u002FvACC glutamate change in response to ketamine based on family history status. In summary, this study will provide key mechanistic information on ketamine's improved antidepressant efficacy in a biologically-enriched subgroup. This will contribute to the systematic development of more efficacious, personalized treatments for major depression in an effort to reduce its enormous public health burden.",[27,123,124],"Major Depression","Alcoholism",[126,123,127],"Ketamine","NMDA Antagonist","2026-04-27",{"date":130,"type":38},"2026-05-01",{"date":132,"type":4},"2014-04-23",{"date":134,"type":21},"2028-09",{"name":136,"class":45},"Mark Niciu",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":46},"100479316","heart-transplantation---renewal-100479316","NCT05521399","Heart Transplantation - Renewal","Comprehensive Cardiac Structure-Function Analysis in Heart Transplantation - Renewal","HeartRenewal","Inclusion Criteria:\n\nAt Northwestern University:\n\n* At least 18 years of age\n* Able to complete the MR safety screening form as required by SOC\n* Able to comprehend and provide informed consent\n\nAdult Heart Transplant patients scanned at CTI\n\n-Baseline cardiac MRI prior to 4\u002F2017\n\nPediatric controls scanned at Lurie\n\n* All ages\n* No known CHD\n* Receiving clinical cardiac MRI: Some pediatric patients are scheduled to receive cardiac -MRI's to rule out congenital heart disease. In some instances, the outcome is normal - these patients would be considered healthy controls. Pediatric controls are getting MRI scans of heart only.\n\nPediatric heart transplant patients scanned at Lurie\n\n* All ages\n* Receiving baseline clinical cardiac MRI\n* Past heart Tx\n\nExclusion Criteria:\n\n* Abnormal kidney function (eGFR \\\u003C 30 mL\u002Fmin\u002F). Patients with a history of kidney problems (GFR \\\u003C 30 ml\u002Fmin) or have had a kidney and\u002For liver transplant will be excluded from the study or may undergo the MRI exam without the use of a contrast agent, per standard MR exclusion criteria\n* Contraindication to MRI i.e. device implants, metal hardware, etc as determined by staff technologists\n* Adults unable to consent\n\nPediatric heart transplant patients scanned at Lurie\n\n* Patients who have not received a heart transplant\n* Patients who have not received a cardiac MRI at baseline\n* Individuals not receiving the supplemental 10-minute scan, due to GA concerns, will be counted towards the desired study population.\n* If a scan returns with an abnormality, they would no longer be considered control and would not be counted towards the desired study population. It is not until the exam is completed the data may be able to determine whether a patient will qualify as a control. Ordering providers routinely order MRI exams to rule out a certain abnormality. This is similar to ordering providers to request a brain MRI if a patient presents with certain symptoms, such as a headache, to rule out a brain tumor. In many cases those exams may return unremarkable.",{"count":146,"type":21},247,"Heart transplantation (HTx) is a well-established life-saving procedure but is associated with severe complications. Regular monitoring of heart transplant recipients is thus important for the early detection of these complications. Current standard clinical tests, however, rely on frequent invasive procedures including endomyocardial biopsies (EMB) and catheter angiography (Cath). In addition, these standard tests are limited by sampling error, the diffuse nature of HTx complications, and high health care utilization cost, estimated at \\>$150,000 per year per patient in the US. To address these limitations, our group has developed a non-invasive multiparametric cardiac MRI, which can quantify abnormal changes in heart tissue and function. Our efforts during the initial period of this study (NIH funded 2014-2019) have focused on the two major complications of HTx: 1) acute cardiac rejection (ACR), the leading cause of death in the first year after heart transplant; and 2) cardiac allograft vasculopathy (CAV), the greatest risk factor for 5-year mortality beyond the first year after heart transplantation. For these major compilation, our previous cardiac MRI studies have identified new non-invasive cardiac MRI measures that can detect abnormalities of heart tissue and function. In addition, the data was able to show that heart donor and recipient mismatch (age, sex, height, weight, etc.) can cause changes in tissue and function of the transplanted heart.",[149,27],"Transplant, Heart","2026-03-20",{"date":152,"type":38},"2026-03-24",{"date":154,"type":38},"2021-11-19",{"date":156,"type":21},"2030-01-31",{"name":158,"class":45},"Northwestern University",{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":81},"100438739","quantitative-t1rho-magnetic-resonance-imaging-in-healthy-subjects-100438739","NCT04993196","Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects","Inclusion Criteria:\n\n\\- Male and female volunteers greater than or equal to 18 years of age\n\nExclusion Criteria:\n\n* Subjects with a contraindication to magnetic resonance imaging such as the presence of metallic implants, claustrophobia and pregnancy.\n* Subjects with previous severe allergic or anaphylactoid reaction to a gadolinium contrast agent, or contraindication to contrast gadolinium administration, such severe renal disease or acutely deteriorating renal function, who would be at risk of nephrogenic systemic fibrosis\n* Subjects who are unable to tolerate the scan without moving the head as a result of symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive impairment, coughing, and shortness of breath.",{"count":166,"type":21},30,[24],"T1rho imaging is a new MRI technique that has strong potential in neuroimaging. This technique does not require exogenous contrast agents and has high spatial resolution.\n\nIn this study we aim to characterise the normal appearance of T1rho in the brain parenchyma in healthy participants. T1rho values will be measured in normal brain structures.",[27],{"date":152,"type":38},{"date":172,"type":38},"2021-08-01",{"date":174,"type":21},"2028-01-31",{"name":176,"class":45},"Chinese University of Hong Kong",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":81},"100330434","mr-guidance-for-liver-and-pancreas-100330434","NCT03582189","MR Guidance for Liver and Pancreas","A Feasibility Study of Magnetic Resonance Imaging (MRI) as a Platform for Image Guidance and Adaptive Radiation Therapy in Patients With Liver or Pancreatic Cancer","Inclusion Criteria:\n\n* Patients 18 years or older\n* Diagnosed with locally advanced pancreatic cancer or hepatocellular carcinoma being considered for treatment with chemoradiation, long course RT, or SBRT with curative intent or palliative intent, planned for 5 or more RT fractions\n\nExclusion Criteria:\n\n\\- Contraindications for MRI: ferromagnetic prosthesis, pacemaker \u002F implanted defibrillator, claustrophobia",{"count":166,"type":21},"This is a single centre, single arm, prospective feasibility study that aims to see whether magnetic resonance imaging (MRI) as a source of image guidance before each radiation treatment fraction is feasible, and also if it may provide information that could potentially be used during the treatment to improve the radiation treatment plan.\n\nPatients will have 5 MRIs with each of their RT sessions. If patients' RT treatment will consist of more than 5 fractions, only 5 MRIs will be done with any 5 RT fractions. Patients will be completing a short questionnaire at the end of each MRI. A patient questionnaire will also be completed at the end of the study to assess for patient satisfaction.\n\nThere will be 30 evaluable patients enrolled to the study.",[27],[188,189,190],"Liver Cancer","Pancreatic Cancer","Radiation","2026-03-03",{"date":193,"type":38},"2026-03-05",{"date":195,"type":38},"2018-07-11",{"date":197,"type":21},"2027-02",{"name":199,"class":45},"University Health Network, Toronto",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":54,"sex":17,"minAge":117,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":81},"100564430","phase-2-brain-blood-vessel-responses-to-changes-in-blood-flow-100564430","NCT06629077","Brain Blood Vessel Responses to Changes in Blood Flow","Cerebrovascular Responses to Acute Hypoperfusion","Inclusion Criteria:\n\n* Between the ages of 55-69 years\n* Have a BMI less than or equal to 34.5 kg\u002Fm2\n* Nonsmoker\n* are less than 72 in (182.88 cm) height\n* Females must be postmenopausal\n\nExclusion Criteria:\n\n* Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)\n* History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis\n* History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia\n* Uncontrolled hypertension\n* History of clinically significant ischemic or hemorrhagic stroke, or significant cerebrovascular disease\n* Severe untreated obstructive sleep apnea\n* History of diabetes with HbA1c greater than 9.5%\n* Major neurologic disorders other than dementia (e.g., MS, ALS, brain surgery, etc.)\n* Current or recent (\\<1 year) major psychiatric condition (Axis I) or addictive disorders\n* Significant surgical history\n* Other significant medical conditions at investigators' discretion\n* Contraindications to MRI\n* Prescribed medications that interfere with prazosin\n* Lactose allergy\n* lower body will not fit in lower body negative pressure (LBNP) chamber (regardless of overall height and BMI).","69 Years",{"count":209,"type":21},36,[120],"Brain blood flow will be measured during a simulated postural change test and while breathing increased levels of carbon dioxide using magnetic resonance imaging.",[27,213],"Cerebrovascular Circulation",[27,215,216,217],"Brain Blood Flow","Lower Body Negative Pressure","Carbon Dioxide","2026-02-27",{"date":220,"type":38},"2026-03-02",{"date":222,"type":38},"2026-02-26",{"date":224,"type":21},"2027-01",{"name":226,"class":45},"University of Wisconsin, Madison",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":81},"100429043","validation-and-implementation-of-3t-mri-research-protocols-100429043","NCT04866940","Validation and Implementation of 3T MRI Research Protocols","VALIDIRM","Inclusion Criteria:\n\n* Male or female, 18 years of age or older\n* Ability to cooperate and remain motionless for up to 1 hour (and lying down for 1.5 hours)\n* Ability to understand the instructions given\n* Subject who has given written and informed consent prior to any examination required by the research)\n* Subject affiliated to a social security system or benefiting from an equivalent system\n\nExclusion Criteria:\n\n* Persons deprived of liberty by judicial or administrative decision\n* Psychiatric disorders, disorders of cognitive functions, not allowing the realization of the MRI\n* Protected adults (subject to a measure of legal protection) or unable to express their consent\n* Subject with Contraindications to MRI",{"count":235,"type":21},230,[24],"The Philips 3T imager installed on the Pavillon Baudot site is an imager dedicated solely to research. It is not located in hospital premises but in INSERM premises for which an authorization for biomedical research has been granted. This equipment is part of the Technical Platform of the UMR 1214 ToNIC whose main objective is the study of the human brain and the main pathologies that affect it.\n\nMRI is an evolving technique, which is used in many research projects. Our technical platform must follow these developments and remain at the cutting edge. One of the essential services of our technical platform is to help set up research protocols and validate acquisition sequences. This development activity is therefore located upstream of research projects involving clinical or fundamental applications. The fact that we can provide our users with a regulatory framework to carry out these development tests for their Research Involving Human Subjects project is a necessity for our research support activity.\n\nThis study aims to provide a generic framework to test the feasibility of MRI sequences requested within the framework of protocols, but also to optimize MRI acquisition sequences already in place, to improve image quality and reduce artifacts that can degrade the quality of the images obtained.\n\nIn France, there are just over 35 centers with MRI dedicated to research and therefore with a validation protocol allowing them to validate their sequences.",[27],"2026-02-13",{"date":241,"type":38},"2026-02-18",{"date":243,"type":38},"2021-05-12",{"date":245,"type":21},"2027-05-12",{"name":247,"class":248},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":81},"100556541","mre-for-diagnosis-of-pancreatic-masses-100556541","NCT06526442","MRE for Diagnosis of Pancreatic Masses","Experimental and Clinical Study of Three-dimensional Magnetic Resonance Elastography to Evaluate Pancreatic Cancer and Interstitial Fibrosis","MREDPCM","Inclusion Criteria:\n\n1. granting of written informed consent\n2. age ≥18 years\n3. no history of extrapancreatic malignancy\n4. no preoperative biliary drainage\n5. definitive histologic evidence of PDAC in excisional biopsy\n6. with no less than three months of postoperative mortality or six months of follow- up\n\nExclusion Criteria:\n\n1. inability to re-review of tissue specimens\n2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection\n3. tumor diameters \\\u003C1.0 cm\n4. withdrawal\u002Fdropout during follow-up","80 Years",{"count":259,"type":21},200,"Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of PDAC. High order three-dimensional MR elastography (3D-MRE) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. However, there are no reports about the application of MRE imaging biomarkers to predict the prognosis of PDAC at home and abroad.",[262,27],"Pancreatic Neoplasm",[264,265],"Pancreatic Cancer, solid pancreatic mass","Magnetic Resonance Elastography","2026-02-12",{"date":239,"type":38},{"date":269,"type":38},"2020-10-09",{"date":271,"type":21},"2027-06-01",{"name":273,"class":45},"Yu Shi",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":284,"studyType":58,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":81},"100475646","taiwan-associated-genetic-and-nongenetic-small-vessel-disease-100475646","NCT05473637","Taiwan Associated Genetic and Nongenetic Small Vessel Disease","Deciphering, Construction and Validation of Magnetic Resonance Imaging Maps, Clinical Features and Outcomes in Genetic and Nongenetic Cerebral Small Vessel Diseases","TAG-SVD","Inclusion Criteria:\n\nParticipants must have at least one of the following symptoms\u002Fsigns or history\n\n* stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ICH or young stroke)\n* cognitive impairment or dementia\n* gait disturbance\n* parkinsonism (especially vascular parkinsonism features)\n* headache (especially migraine)\n* positive family history of hereditary CSVD\n* MRI evidence of CSVD (MRI may be done for other reasons), including mild to moderate white matter hyper intensity, any lacune, or any cerebral microbleed\n\nExclusion Criteria:\n\n* MRI evidence of CSVD due to other inflammatory, malignancy, or structural lesions\n* patients or family members not willing to sign informed consent",{"count":283,"type":21},500,"2 Years","The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be followed for at least 2 years.",[287,288,289,290,291,27,292,293],"Cerebral Small Vessel Diseases","Cadasil","HTRA1-Related Autosomal Dominant Cerebral Angiopathy","COL4A1-Related Brain Small Vessel Disease With Haemorrhage","Fabry Disease","Next-generation Sequencing","Stroke","2026-01-15",{"date":296,"type":38},"2026-01-20",{"date":298,"type":38},"2019-01-01",{"date":300,"type":21},"2028-12-31",{"name":302,"class":45},"National Taiwan University Hospital",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":311,"minAge":18,"maxAge":89,"enrollmentInfo":312,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":314,"conditions":315,"keywords":321,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":81},"100499146","endometriosis---mri-100499146","NCT05779462","ENDOMETRIOSIS - MRI","Study of Pelvic Organ Mobility by Dynamic MRI in Pelvic Endometriosis","ENDO-MRI","Inclusion Criteria:\n\n* Patient referred for suspected pelvic endometriosis requiring pelvic MRI\n* Female, nulliparous,\n* patient with signed written consent, patient with health insurance,\n* patient willing to comply with all study procedures and duration\n\nExclusion Criteria:\n\n* BMI \\> 35,\n* history of hereditary collagen and elastic tissue disease,\n* history of pelviperitonitis,\n* history of major pelvic surgery,\n* inability to receive informed information,\n* inability to participate in the entire study,\n* lack of social security coverage,\n* refusal to sign consent","FEMALE",{"count":313,"type":21},52,"Endometriosis is a frequent pathology with an estimated prevalence of 10% of women of childbearing age. There is no exact correspondence between the symptoms described by the patients and the severity of the lesions, which makes clinical diagnosis difficult. It therefore seems important to improve the complementary examinations available to make the diagnosis more precise and to better study the effectiveness of the treatments implemented. The clinical examination and per-surgical findings of patients with deep pelvic endometriosis show a clear decrease in the mobility of the pelvic organs in relation to each other, but few studies have looked at this mobility, which could however have an implication in explaining the pathophysiology of the disease and the symptomatology of the patients, as well as in the detection of lesions preoperatively. The persistence of hypo-mobility could also help to understand treatment failures.",[316,317,27,318,319,320],"Endometriosis","Mobility Limitation","Diagnosis","Pelvis","Comparative Study",[322,317,323,319,320],"Endometriosis ;","Magnetic Resonance Imaging, Cine","2025-12-18",{"date":326,"type":38},"2025-12-26",{"date":328,"type":38},"2023-05-23",{"date":330,"type":21},"2026-07",{"name":332,"class":45},"University Hospital, Lille",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":205,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":54,"sex":17,"minAge":339,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":211,"conditions":343,"keywords":344,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":81},"100564431","phase-2-brain-blood-vessel-responses-to-changes-in-blood-flow-younger-cohort-100564431","NCT06629090","Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort","Inclusion Criteria:\n\n* Between the ages of 20-40 years\n* Have a BMI ≤34.5 kg\u002Fm2\n* are less than 72 in (182.88 cm) height\n* Nonsmoker\n\nExclusion Criteria:\n\n* Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD)\n* History or evidence of hepatic disease, hematological disease, or peripheral vascular disease; severe kidney injury requiring hemodialysis\n* History of cardiovascular disease including: severe congestive heart failure, coronary artery disease, ischemic heart disease (stents, coronary artery bypass grafts) and tachycardia\n* Uncontrolled hypertension\n* History of clinically significant ischemic or hemorrhagic stroke, or significant cerebrovascular disease\n* Severe untreated obstructive sleep apnea\n* History of diabetes with HbA1c greater than 9.5 percent\n* Major neurologic disorders other than dementia (e.g., MS, ALS, brain surgery, etc.)\n* Current or recent (less than1 year) major psychiatric condition (Axis I) or addictive disorders\n* Significant surgical history\n* Other significant medical conditions at investigators' discretion\n* Contraindications to MRI\n* Prescribed medications that interfere with prazosin\n* Lactose allergy\n* lower body will not fit in lower body negative pressure (LBNP) chamber (regardless of overall height and BMI)","20 Years","40 Years",{"count":209,"type":21},[120],[27,213],[27,215,216,217],"2025-12-17",{"date":324,"type":38},{"date":345,"type":38},{"date":349,"type":21},"2026-12",{"name":226,"class":45},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":357,"minAge":340,"maxAge":117,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":360,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":81},"100468803","utility-of-biparametric-mri-magnetic-resonance-imaging-as-a-screening-tool-for-prostate-cancer-in-a-high-risk-cohort-100468803","NCT05384535","Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort","Inclusion Criteria:\n\n1. PSA between 1.0 and 2.5 ng\u002FdL\n2. High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate cancer (father, brother) or specific genetic syndromes i.e. BRCA 1\u002F2, HOX B13, Lynch syndrome, ATM, CHEK2\n3. Patient is willing to participated in prostate cancer screening\n4. Patient is capable of giving informed consent\n\nExclusion Criteria:\n\n1. Nodularity or firmness of prostate on exam\n2. Patient has undergone a prior biopsy or prostate surgery\n3. Patient is taking 5-alpha reductase inhibitors to manage benign prostatic hyperplasia, as this can significantly alter PSA levels.\n4. Patient has a history of UTI or prostatitis in the preceding 6 months, as this can significantly alter PSA levels.\n5. Patient has a contraindication to MRI, these include but are not limited to pacemakers, neurostimulator devices, metal cardiac valves, certain tattoos, or foreign bodies\n6. Participants that experience claustrophobia, anxiety and\u002For vertigo when moved inside the scanner\n7. The participant cannot tolerate lying flat for the study duration","MALE",{"count":359,"type":21},100,[24],"To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.",[363,27,364],"Prostate Cancer","Population at Risk",[363,366,27],"Screening","2025-11-19",{"date":369,"type":38},"2025-11-24",{"date":371,"type":38},"2022-08-15",{"date":373,"type":21},"2028-10-31",{"name":375,"class":45},"Northwell Health",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":383,"maxAge":257,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":387,"conditions":388,"keywords":396,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":81},"100571845","integrative-medicine-in-pain-management-in-sickle-cell-disease-20-100571845","NCT06725550","Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0","Integrative Medicine in Pain Management in Sickle Cell Disease: Assessing the Clinical Efficacy and Neurobiological Impact With Acupuncture, 2.0","Inclusion Criteria:\n\n* Any gender\n* 14-17 (Adolescents) and 18-80 (Adults) years old\n* Right-handed\n* Either outpatient or inpatient or status changing between each other\n* Have been diagnosed with SCD (includes but not limited to SS, SC or other type) and experiencing chronic pain in the past 6 months or vaso-occlusive crisis (VOC) in the past 12 months.\n* Analgesic therapy prescribed by primary hematologists (or physicians for emergency or primary care) including pain-relieving medications (e.g. Morphine, coderin, Fentanyl, Oxycodone), Hydroxyurea (e.g. Droxia, Hydrea, Siklos), L-glutamine oral powder (Endari), Crizanlizumab (Adakveo), Voxelotor (Oxbryta), and\u002For other palliative treatment allowed, not required.\n* Willing to limit the current and the introduction of any new medications or treatment modalities for control of pain symptoms during the study visits.\n* Able to travel to the study site for participating scheduled visits (questionnaires, QST, EEG and MRI) and receive acupuncture treatments up to two times weekly for 5 weeks as scheduled.\n* We will recruit without regard to ethnicity, however, due to the genetic nature of SCD, subjects will primarily be African-American or of African descent, although there are individuals with SCD who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. The ethnic distribution in our prior studies is 95% Black\u002FAfrican American with 5% Hispanic or Latino (of any race). As these are minority groups many individuals may be from lower income situations.\n* Fluent in English and capable of giving written informed consent.\n\nExclusion Criteria:\n\n* Subjects with Covid-19 suspicion or confirmation\n* Recent\u002Fongoing alternative pain management with acupuncture or acupuncture-related techniques within the last 6-months.\n* Presence of a known coagulation abnormality: Thrombocytopenia (mild thrombocytopenia with a platelets range of 51,000-100,000\u002Ful will be further evaluated for inclusion consideration), or bleeding diathesis that may preclude the safe use of acupuncture.\n* Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. that causes pain or any other chronic pain condition with pain greater than sickle pain.\n* Diseases\u002Fconditions history includes but not limited to:\n\n  * head injury with substantial loss of consciousness\n  * peripheral neuropathy of known cause that interferes with activities of daily living\n  * known non-SCD related Severe psychiatric illnesses (e.g. current schizophrenia, major depression with suicidal ideation).\n  * significant visual, motor, or auditory impairment that would interfere with ability to perform study visits-related activities\n* Medication:\n\nRecent (30 days) initiation or dose adjustment of stimulant medications, such as those used to treat ADD\u002FADHD (e.g., amphetamine\u002Fdextroamphetamine \\[Adderall®\\], methylphenidate, dextroamphetamine), or the fatigue associated with sleep apnea or shift work (e.g., modafinil).\n\n* Contraindications to MRI scans includes but are not limited to: surgical clips, surgical staples, metal implants, cardiac rhythmic disorders, seizure disorders, and certain metallic dental material will not be scheduled for MRI visits.\n* History vascular surgery in lower limbs or current lower limb vascular dysfunction will not receive conditioned pressure pain stimuli in the lower limb.\n* Subjects with Worker's Compensation, Workman's Compensation, civil litigation or disability claims pertinent to the subject's sickle disease; current involvement in out-of-court settlements for claims pertinent to the subject's sickle disease; or currently receiving monetary compensation as a result of any of the above.\n* Participation of other studies: Concurrent participation in other therapeutic trials with overlapping research purposes.\n* Pregnant or nursing.","14 Years",{"count":385,"type":21},120,[24],"The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.",[389,390,391,392,27,393,394,395],"Sickle Cell Disease","Pain","Acupuncture","Quantitative Sensory Testing","Circulating Biomarkers","Electroencephalography","Functional Near-infrared Spectroscopy",[397,390,391,392,27,393,394,395],"Sickle cell disease","2025-10-15",{"date":400,"type":38},"2025-10-20",{"date":402,"type":38},"2025-08-25",{"date":404,"type":21},"2030-08-30",{"name":406,"class":45},"Indiana University",{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":81},"100515499","feasibility-testing-of-7-tesla-magnetic-resonance-imaging-100515499","NCT05992298","Feasibility Testing of 7-Tesla Magnetic Resonance Imaging","Explorative Technical Feasibility Testing of 7-Tesla Magnetic Resonance Imaging of the Musculoskeletal System and of the Head","Inclusion Criteria:\n\n* Consent to undergo a 7T (and, if appropriate a comparative 3T) MRI exam.\n* For some of the consistent small series: presence of a specific condition of the musculoskeletal system or of the head. This can include traumatic or degenerative changes, e.g., of tendons, cartilage, muscle, peripheral nerves, ligaments, and bones, or in the brain, as well as focal lesions, e.g., tumors.\n\nExclusion Criteria:\n\n* Contraindications to undergo a MRI examination at a field strength of 7 Tesla or at 3 Tesla.\n* Irregular anatomy and\u002For tissue properties\n* Inability to consent - for any reason.\n* Body mass above 200 kg.\n* Body mass below 30 kg.\n* Women: pregnancy.\n* Age below 18.\n* Known or suspected non-compliance, drug or alcohol abuse.\n* Inability to follow the procedures of the study.",{"count":415,"type":21},780,[24],"The goal of the current project is to explore and develop the technical feasibility of non-invasive imaging of the human musculoskeletal system and head with the first 7T MR scanner with a CE mark to identify areas where the higher field promises significant benefits in qualitative image quality. For a subset of the planned exams, state-of-the art 7T or 3T images will be used as standard of reference to comparatively gauge the qualitative image quality of the investigational 7T images.",[27],"2025-10-01",{"date":421,"type":38},"2025-10-02",{"date":423,"type":38},"2023-08-07",{"date":425,"type":21},"2028-02-29",{"name":427,"class":45},"Reto Sutter, MD",{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":81},"100396705","7-tesla-mri-evaluation-of-the-spine-asymptomatic-100396705","NCT04445584","7 Tesla MRI Evaluation of the Spine (Asymptomatic)","7 Tesla MRI Evaluation of the Spine","Inclusion criteria:\n\n* Informed consent as documented by signature (Appendix Informed Consent Form)\n* \\>18 years old\n* Patients presenting chronic back pain (\\> 2 months) without recent trauma, previous MRI (1,5 or 3T) for clinicals indications or asymptomatic individuals (for depicting normal microanatomy)\n\nExclusion criteria:\n\n* previous surgery\n* tumor patients\n* pregnancy or breast feeding\n* any MRI contra-indications\n* any MRI contra-indications",{"count":436,"type":21},600,"High-resolution MRI (7 Tesla) of the cervical spine is capable to provide good differentiation between nerve and surrounding tissues within foramen und allows to reliably quantify the diameter of nerve roots\u002Fganglia. Secondly, detailed anatomy of vertebral artery and its relation to neural structures \u002F foramina can be assessed.",[27,439,440],"Cervical Spine Anatomy","Reference Standard",{"date":421,"type":38},{"date":443,"type":38},"2020-06-01",{"date":445,"type":21},"2027-09-30",{"name":447,"class":45},"Balgrist University Hospital",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":311,"minAge":18,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":22,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":81},"100584663","the-fyi-on-mri-a-multilevel-decision-support-intervention-for-screening-breast-mri-100584663","NCT06892275","The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI","Inclusion Criteria:\n\n* female\n* aged 18-74 years\n* self-identifying as Black and\u002For Latina\n* no personal history of breast cancer\n* English- or Spanish-speaking\n* having received a mammogram with normal results in the last 12 months\n* ≥20% lifetime breast cancer risk per the NCI Breast Cancer Risk Assessment Tool (BCRAT)\n\nExclusion Criteria:\n\n* aged \\\u003C18 or ≥75\n* pregnancy","74 Years",{"count":456,"type":21},80,[24],"The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.",[460,461,462,27],"Breast Neoplasm Female","Early Detection of Cancer","Hereditary Breast and Ovarian Cancer Syndrome","2025-09-26",{"date":465,"type":38},"2025-09-30",{"date":467,"type":38},"2025-06-01",{"date":469,"type":21},"2027-12",{"name":471,"class":45},"Georgetown University",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":491,"leadSponsor":493,"locationsCount":81},"100603611","role-of-mri-in-the-early-diagnosis-and-management-of-acute-stroke-and-its-impact-on-turnaround-time-in-emergency-settings-100603611","NCT07138768","Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Settings","The Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time (TAT) in Emergency Settings","Inclusion Criteria:\n\n* Age ≥18 years.\n* Both sexes.\n* Patients with acute stroke who are admitted to the emergency department.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or computed tomography (CT).\n* Symptoms strongly suggestive of subarachnoid hemorrhage.\n* Initiation of antithrombotic or thrombolytic treatment before the completion of both scans.\n* Inability to complete both scans in time to allow thrombolytic treatment within three h of the onset of symptoms.\n* Uncontrollable hypertension.\n* Pregnant or lactating women.",{"count":480,"type":21},136,"This study aims to evaluate the role of stroke protocol in the early diagnosis and management of acute stroke and its effect on turnaround time (TAT) in emergency settings.",[27,318,483,484,485,486],"Management","Acute Stroke","Turnaround Time","Emergency Settings","2025-08-23",{"date":489,"type":38},"2025-08-26",{"date":487,"type":38},{"date":492,"type":21},"2026-12-01",{"name":494,"class":45},"Tanta University",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":513,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":46},"100376977","serial-mri-scans-during-radiation-therapy-100376977","NCT04188535","Serial MRI Scans During Radiation Therapy","RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes During Treatment With Radiation Therapy","RELAY","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring radiation therapy.\n* Age: 18 years or older except where otherwise specified in subprotocol.\n* ECOG performance status ≤2 (Karnofsky ≥60%)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Any further criteria listed in the specific disease site subprotocol.\n* (Esophageal cohort) Patients must be considered appropriate candidates for neoadjuvant chemoradiation therapy followed by esophagectomy. Patients must have an endoscopic ultrasound done or scheduled to be done at the baseline visit.\n* (Glioblastoma cohort) Patients with a histologically confirmed newly diagnosed intracranial glioblastoma or gliosarcoma who will be undergoing radiation therapy as part of clinical care.\n* (Prostate cohort) Patients with localized prostate cancer who are planning to receive androgen deprivation therapy and definitive radiation therapy.\n* (Vulvar cohort) Patients with biopsy-proven locally advanced vulvar cancer for which definitive radiotherapy is planned.\n* (Pediatric glioma cohort) Patients age 18 or under (patients 18-30 years old are also eligible if the physician determines that based on genetics, the tumor biology is consistent with pediatric high grade glioma). Patients with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care. Patients with DIPG are only eligible if biopsy-confirmed high grade DIPG is present. Ability to understand and\u002For willingness of their parent or legally authorized representative to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Disease-specific exclusion criteria will be specified in a subprotocol.\n* For MRI involving contrast, history of allergic reactions attributed to gadolinium-based IV contrast. If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility.\n* Inability to undergo magnetic resonance imaging (MRI).",{"count":504,"type":21},149,[24],"This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.\n\nThe research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma.\n\nThe research study procedures include:\n\n* Screening for eligibility\n* Three MRI scans",[508,509,510,27,32,363,511,512],"Glioblastoma","Esophageal Cancer","Radiotherapy","Vulvar Cancer","Pediatric Glioblastoma Multiforme",[508,509,510,27,32,363,511,512],"2025-08-20",{"date":489,"type":38},{"date":517,"type":38},"2020-01-15",{"date":519,"type":21},"2030-07-31",{"name":521,"class":45},"Dana-Farber Cancer Institute",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":54,"sex":17,"minAge":117,"maxAge":4,"enrollmentInfo":530,"targetDuration":531,"studyType":58,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":81},"100602025","memory-deterioration-in-alzheimer-disease-100602025","NCT07118137","Memory Deterioration in Alzheimer Disease","Translational Neuroscience CAG for Alzheimer's Disease","MemAD","Inclusion Criteria:\n\n* Confirmed diagnosis based on current ICD criteria for AD or MCI .\n* \\>55years.\n* Norwegian native speaker\n* Lives at home and not in a health institution\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \\> 2).\n* Presence of brain tumors.\n* History of traumatic brain injury.\n* History of cranial surgery.\n* Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG).\n* Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS.\n\n  7T MRI contraindications:\n* Large tattoos close to the head region, permanent makeup or unremoveable piercings\n* Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred)\n* Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)",{"count":166,"type":21},"1 Year","Semantic AD",[534,535,27,536],"Alzheimer Disease","Neurodegenerative Diseases","Memory Impairment","2025-08-04",{"date":539,"type":38},"2025-08-12",{"date":541,"type":38},"2023-10-15",{"date":543,"type":21},"2027-12-31",{"name":545,"class":45},"Norwegian University of Science and Technology",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":81},"100598281","prognostic-value-of-isolated-and-combined-score-aspects-in-acute-ischemic-stroke-100598281","NCT07069452","Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke","TARGET-ASPECT (Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke)","Inclusion Criteria :\n\n* Patients aged 18 years or older\n* Confirmed acute ischemic stroke on imaging\n* Treated with both thrombolysis and thrombectomy\n* Clinical follow-up data available at 90 days (mRS score)\n\nExclusion Criteria :\n\n* Primary hemorrhagic stroke\n* Early death or loss to follow-up without evaluation\n* Poor-quality imaging that cannot be analyzed",{"count":554,"type":21},152,"This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.",[557,558,559,560,561,27,562],"Stroke, Ischemic","Thrombectomy","Thrombolytic Therapy","Brain Ischemia","Prognosis","Outcome Assessment (Health Care)","2025-07-15",{"date":565,"type":38},"2025-07-16",{"date":567,"type":38},"2025-04-15",{"date":294,"type":21},{"name":570,"class":45},"Centre Hospitalier de Gonesse",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":578,"enrollmentInfo":579,"targetDuration":581,"studyType":58,"phases":4,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":81},"100558945","exploring-the-characteristics-of-epileptogenic-foci-in-drug-resistant-epilepsy-based-on-multimodal-imaging-technology-100558945","NCT06557720","Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology","Exploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Using Multimodal Imaging Techniques: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n1. Aged ≥18 years old;\n2. Meet the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy;\n3. Duration of epilepsy ≥2 years, with an average seizure frequency of ≥2 times per month in the 3 months prior to enrollment;\n4. Adequate intake of two or more anti-epileptic drugs, with no intervention in the treatment plan during the trial period;\n5. Capable of cooperating to complete treatment and related examination items; The patient and family fully understand and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. In a state of continuous epileptic seizures;\n2. Complicated with severe infections, cerebrovascular diseases, malignant tumors, and other diseases, accompanied by severe dysfunction of the heart, liver, kidney, or other organs, or with mental disorders, or with uncorrectable hyperglycemia, or 3.patients on long-term use of corticosteroid medications;\n\n4.Pregnant or lactating women; 5.Contraindications for PET, MR, EEG examinations; 6.Patients with examinations (with ferromagnetic metal implants in the body; high fever); 7.Participating in other clinical trials at the same time; 8.The patient or family withdraws the informed consent form.","65 Years",{"count":580,"type":21},50,"2 Months","Using multimodal imaging technology, this study aims to explore the characteristics of epileptogenic foci in patients with drug-resistant epilepsy and identify key network nodes (such as central nodes) to provide more assistance for the diagnosis of drug-resistant epilepsy.",[584,27,585],"Drug Resistant Epilepsy","Electroencephalogram (EEG)","2025-06-23",{"date":588,"type":38},"2025-06-25",{"date":590,"type":38},"2024-06-11",{"date":592,"type":21},"2027-08-01",{"name":594,"class":45},"Xijing Hospital",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":610,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":81},"100382293","qualitative-and-quantitative-evaluation-of-vascular-flows-of-radial-ulnar-and-interdigital-arterial-trees-under-normal-and-pathological-conditions-by-3-tesla-mri-100382293","NCT04257747","Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI","FLOWHAND","Inclusion Criteria:\n\n* Adult (≥ 18 years old)\n* patients who has received appropriate information and provided informed consent\n* patients benefiting from social security insurance\n* patients with no contraindications to magnetic resonance imaging\n* healthy volunteer or patient requiring radial forearm flap reconstruction or having received hand allotransplantation.\n\nExclusion Criteria:\n\n* Person with a contraindication to MRI\n* pregnant or breastfeeding woman\n* minors (\\\u003C 18 years)\n* person under guardianship or deprived of liberty by a judicial or administrative decision\n* person with upper limb arteriopathy with the exception of the hand transplant patients group.",{"count":603,"type":21},46,[24],"Allotransplants of vascularized composite tissues are subject to chronic vascular rejection, which can lead to graft loss. Currently, no imaging technique allows a reproducible quantitative exploration of the arterial trees of the hand, and therefore a satisfactory monitoring of transplants. Since 2014, flow MRI has been applied to the analysis of small-calibre arteries by the Image Processing Team at the Amiens-Picardie University Hospital. Between 2015 and 2017, several acquisitions were made in 3 patients who received facial allotransplantation, and the team recently developed a flow MRI protocol dedicated to the study of arterial trees in the hand.\n\nThe main objective is to measure vascular flows of radial, ulnar and interdigital arterial trees in normal (healthy volunteers) and pathological situations (patients with radial forearm flap reconstruction and patients with hand allotransplantation) using the specifically developed flow MRI protocol.",[27,607,608,609],"Vascular Complications","Transplantation","Radial Artery",[611,612,613,614,615,616,617],"vascularized composite allotransplantation","hand allotransplantation","radial forearm flap","magnetic resonance imaging","flow MRI","radial artery","ulnar artery","2025-06-05",{"date":620,"type":38},"2025-06-10",{"date":622,"type":38},"2021-09-01",{"date":624,"type":21},"2029-03",{"name":626,"class":45},"Centre Hospitalier Universitaire, Amiens",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":81},"100537397","prognotic-role-of-cmr-in-takotsubo-syndrome-100537397","NCT06277297","Prognotic Role of CMR in Takotsubo Syndrome","Exploring the eVolution in prognOstic capabiLity of mUlti-sequence Cardiac magneTIc resOnance in patieNts Affected by Takotsubo Cardiomyopathy","EVOLUTION","Inclusion Criteria:\n\n* Takotsubo syndrome diagnosis (according to Position Statement of the European Society of Cardiology Heart Failure Association)\n* Adult patients ( \\> 18y old)\n* Availability at baseline of clinical variables, standard transthoracic echocardiography, and cardiovascular magnetic resonance acquisition\n\nExclusion Criteria:\n\n* \\\u003C18 y old\n* Lack of transthoracic echocardiography and cardiovascular magnetic resonance examinations\n* Preexisting cardiomyopathies\n* Previous myocardial infarction\n* Suspected or known prior irreversible myocardial damage\n* Valvular heart disease",{"count":636,"type":21},350,"The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome.\n\nThe secondary objectives of this registry are as follows:\n\nInvestigate the diagnostic value of cardiac magnetic resonance parameters in predicting in-hospital and long-term outcomes in patients with Takotsubo syndrome.\n\nCompare the proposed risk stratification score for patients with Takotsubo syndrome with previously existing scores.\n\nInvestigate the contribution of machine learning models in predicting in-hospital and long-term outcomes compared to standard clinical scores.\n\nThe design and rationale of this registry are available at 10.1097\u002FRTI.0000000000000709",[639,640,27],"Takotsubo Cardiomyopathy","Machine Learning","2025-06-04",{"date":643,"type":38},"2025-06-08",{"date":645,"type":38},"2022-11-09",{"date":647,"type":21},"2032-11",{"name":649,"class":45},"University of Cagliari"]